Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma (GBM) is the most aggressive adult brain tumor.
• Multidrug resistance (MDR) to chemotherapy, like temozolomide, is a major cause of treatment failure in GBM.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their role in cancer development and drug resistance.

Purpose of the Study:

• To review the contribution of lncRNAs to the regulation of MDR in glioblastoma.
• To elucidate the underlying molecular mechanisms by which lncRNAs mediate MDR in GBM.
• To identify potential therapeutic strategies targeting lncRNAs for overcoming glioblastoma treatment resistance.

Main Methods:

• Literature review of studies investigating lncRNAs and MDR in glioblastoma.
• Analysis of molecular mechanisms involving lncRNA-mediated regulation of drug resistance pathways.
• Synthesis of current knowledge on lncRNA functions in glioblastoma multidrug resistance.

Main Results:

• lncRNAs are implicated in various MDR mechanisms in glioblastoma, including altered drug transport, DNA repair, and apoptosis evasion.
• Specific lncRNAs have been identified as key regulators of temozolomide resistance and other chemotherapeutic agent resistance in GBM.
• lncRNA expression profiles can serve as potential biomarkers for predicting treatment response in glioblastoma patients.

Conclusions:

• lncRNAs are critical regulators of multidrug resistance in glioblastoma.
• Targeting lncRNAs presents a promising therapeutic avenue for overcoming treatment resistance in GBM.
• Further research into lncRNA mechanisms can lead to novel strategies for improving glioblastoma patient outcomes.